M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 52 of 54
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00085384
Fibrin Melanoma Axillary Node Study in Patients With Melanoma
NCT00504582
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
NCT00068575
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
NCT00038571
Computer-Assisted Counseling in Helping African American Smokers Stop Smoking
NCT00310141
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
NCT00038623
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
NCT00310115
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
NCT00024167
Gleevec Study for Patients With Ovarian Cancer
NCT00510653
Combined Colon and Endometrial Cancer Screening in Women With HNPCC
NCT00510796
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
NCT01039025
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
NCT00505492
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00501345
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00897806
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
NCT00080782
FM 140 vs FM100 Study in Patients With Multiple Myeloma
NCT00505895
Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes
NCT00529230
PP-Gemcitabine & External Beam Radiation-Sarcomas
NCT02046304
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
NCT00038415
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
NCT00037869
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
NCT00038558
Reflectance Confocal Imaging in Cervical Cancer Patients
NCT00505726
Celecoxib as a Chemopreventive Agent in Current and Former Smokers
NCT00981201
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
NCT00254436
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
NCT00038194
Study of Vioxx and Radiation Therapy for Brainstem Glioma
NCT00038389
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
NCT00038493
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
NCT00061620
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
NCT00027586
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
NCT00038857
Mifepristone for Patients With Endometrial Cancer and LGESS
NCT00505739
Primary Breast Cancer Occurring Concomitant With Pregnancy
NCT00510367
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
NCT00502203
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
NCT00080808
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
NCT00023881
Late Chronic Phase Chronic Myelogenous Leukemia
NCT01092741
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
NCT00080795
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
NCT00038844
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
NCT00038675
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
NCT00283582
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
NCT00038649
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00038545
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
NCT00038831
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
NCT00038805
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
NCT00038818
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
NCT00038597
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
NCT00038883
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
NCT00077142
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
NCT00038402
Papillary Serous Carcinoma of the Endometrium
NCT00515073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.